Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

The clinical benefit of cusatuzumab, a CD70‐directed monoclonal antibody with enhanced effector functions, was investigated in patients with relapsed/refractory (R/R) cutaneous T‐cell lymphoma (CTCL).

[1]  R. Bruggmann,et al.  Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents , 2020, Nature Medicine.

[2]  E. Swart,et al.  Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment , 2020, AntiCancer Research.

[3]  T. Kupper,et al.  Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem , 2019, Clinical Cancer Research.

[4]  S. Whittaker,et al.  IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. , 2019, The Lancet. Oncology.

[5]  Sean P. Palecek,et al.  Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies , 2019, Nature Communications.

[6]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[7]  D. Isenberg,et al.  Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus , 2018, Annals of the rheumatic diseases.

[8]  P. Zinzani,et al.  Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. , 2017, Cancer treatment reviews.

[9]  A. Toubert,et al.  Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity. , 2017, Blood.

[10]  M. Weichenthal,et al.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial , 2017, The Lancet.

[11]  J. Soria,et al.  Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies , 2017, Clinical Cancer Research.

[12]  T. Pabst,et al.  CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia , 2017, The Journal of experimental medicine.

[13]  R. Wilcox,et al.  Cutaneous T‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management , 2016, American journal of hematology.

[14]  B. Poligone,et al.  Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy , 2015, Current Hematologic Malignancy Reports.

[15]  P. Pauwels,et al.  CD70: An emerging target in cancer immunotherapy. , 2015, Pharmacology & therapeutics.

[16]  P. V. Van Schil,et al.  Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer , 2015, Oncotarget.

[17]  R. Radpour,et al.  CD70/CD27 Signaling Mediates Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors By Compensatory Activation of the Wnt Pathway , 2014 .

[18]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Clark,et al.  Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. , 2014, JAMA dermatology.

[20]  H. Wajant,et al.  ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade , 2014, mAbs.

[21]  F. Jardin,et al.  The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B‐cell lymphoma , 2013, Genes, chromosomes & cancer.

[22]  Jinming Yu,et al.  Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas , 2013, OncoTargets and therapy.

[23]  R. Clark,et al.  Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients , 2012, Science Translational Medicine.

[24]  James J. Campbell,et al.  Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. , 2010, Blood.

[25]  S. Iida,et al.  Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. , 2009, Experimental hematology.

[26]  B. Cheson.  New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. , 2008, Radiologic clinics of North America.

[27]  Haralampos J. Milionis,et al.  Cutaneous T-cell lymphoma. , 2005, The Journal of dermatologic surgery and oncology.

[28]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[29]  M. Nikolova,et al.  Crosstalk between Tumor T Lymphocytes and Reactive T Lymphocytes in Cutaneous T Cell Lymphomas , 2001, Annals of the New York Academy of Sciences.

[30]  J. Boer,et al.  Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. , 2009, Blood.